Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0061 intravenous phase I/II study in rheumatoid arthritis
NL-OMON36644Phase 2Withdrawn
- Sponsor
- Ablynx
- Start
- Dec 2010
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ALX-0061 plus background methotrexate with Placebo plus background methotrexate (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Planned start Dec 2010; status: withdrawn.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36644.